Your browser is no longer supported. Please, upgrade your browser.
DNLI Denali Therapeutics Inc. daily Stock Chart
DNLI [NASD]
Denali Therapeutics Inc.
Index- P/E- EPS (ttm)-0.68 Insider Own1.10% Shs Outstand95.17M Perf Week3.50%
Market Cap1.80B Forward P/E- EPS next Y-2.47 Insider Trans-7.66% Shs Float87.57M Perf Month24.75%
Income-66.10M PEG- EPS next Q-0.57 Inst Own86.00% Short Float11.00% Perf Quarter-4.21%
Sales147.70M P/S12.18 EPS this Y61.20% Inst Trans-0.43% Short Ratio28.08 Perf Half Y-3.32%
Book/sh4.57 P/B4.14 EPS next Y-18.70% ROA-10.20% Target Price25.90 Perf Year-7.35%
Cash/sh5.04 P/C3.75 EPS next 5Y- ROE-13.40% 52W Range14.24 - 28.86 Perf YTD-8.52%
Dividend- P/FCF- EPS past 5Y- ROI-8.50% 52W High-34.52% Beta-
Dividend %- Quick Ratio10.60 Sales past 5Y- Gross Margin- 52W Low32.72% ATR0.75
Employees255 Current Ratio10.60 Sales Q/Q1038.40% Oper. Margin-54.60% RSI (14)68.85 Volatility3.78% 4.26%
OptionableYes Debt/Eq0.00 EPS Q/Q-27.80% Profit Margin-44.70% Rel Volume0.57 Prev Close18.73
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume343.03K Price18.90
Recom2.30 SMA209.22% SMA5016.93% SMA200-3.96% Volume195,227 Change0.91%
Sep-26-19Initiated Wedbush Neutral $19
Sep-13-19Initiated Nomura Buy
Aug-09-19Initiated BTIG Research Buy $30
Jun-26-19Initiated H.C. Wainwright Buy $28
Nov-15-18Initiated Cantor Fitzgerald Overweight $25
Nov-12-18Initiated Janney Buy
Mar-12-18Downgrade Evercore ISI Outperform → In-line
Jan-02-18Initiated Morgan Stanley Overweight
Jan-02-18Initiated JP Morgan Overweight $24
Jan-02-18Initiated Goldman Neutral $19
Jan-02-18Initiated Evercore ISI Outperform $23
Dec-03-19 08:58AM  Options Traders Expect Huge Moves in Denali (DNLI) Stock Zacks
Nov-06-19 07:25PM  Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:30PM  Denali Therapeutics Reports Third Quarter 2019 Financial Results and Business Highlights GlobeNewswire
Oct-27-19 11:08AM  Were Hedge Funds Right About Ditching Denali Therapeutics Inc. (DNLI)? Insider Monkey
Sep-04-19 09:00AM  Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL151 for Parkinsons Disease and Launch of Its Engage Parkinsons Website GlobeNewswire
Aug-06-19 08:05PM  Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Lags Revenue Estimates Zacks
04:30PM  Denali Therapeutics Reports Second Quarter 2019 Financial Results and Business Highlights GlobeNewswire
Aug-05-19 09:00AM  Denali Therapeutics Announces That Its Partner Sanofi has Commenced Dosing of DNL758 in a Phase 1 Study GlobeNewswire
Aug-01-19 10:33AM  Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q2 Release Zacks
Jul-04-19 06:03AM  Is Denali Therapeutics Inc. (NASDAQ:DNLI) A Financially Strong Company? Simply Wall St.
Jun-29-19 06:27PM  Hedge Funds Have Never Been This Bullish On Denali Therapeutics Inc. (DNLI) Insider Monkey
Jun-12-19 10:30AM  Denali's Hunter Syndrome Candidate Gets Orphan Drug Status Zacks
Jun-11-19 09:00AM  Denali Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designation for DNL310, and Expands its Portfolio of Brain Penetrant Enzyme Replacement Programs GlobeNewswire
May-08-19 08:05PM  Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:30PM  Denali Therapeutics Reports First Quarter 2019 Financial Results GlobeNewswire
May-03-19 10:30AM  Analysts Estimate Denali Therapeutics Inc. (DNLI) to Report a Decline in Earnings: What to Look Out for Zacks
May-01-19 05:43PM  Controversial Alzheimer's Disease theory could pinpoint new drug targets American City Business Journals
Apr-30-19 02:52PM  Heres What Hedge Funds Think About Denali Therapeutics Inc. (DNLI) Insider Monkey
Apr-15-19 03:00PM  Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's American City Business Journals
Apr-10-19 10:03AM  3 Biotech Stocks That Doubled After Hitting Bottom in 2018 Motley Fool
Apr-02-19 02:46PM  Did Denali Therapeutics's (NASDAQ:DNLI) Share Price Deserve to Gain 26%? Simply Wall St. +6.30%
Mar-14-19 02:42PM  Harry Boxers 4 stocks running on earnings MarketWatch
Mar-12-19 10:35AM  Denali Therapeutics Inc. (DNLI) Q4 Earnings and Revenues Surpass Estimates Zacks
09:00AM  Denali Therapeutics Reports Full Year 2018 Financial Results and Business Highlights GlobeNewswire
Feb-19-19 07:55AM  New Research: Key Drivers of Growth for Walgreens Boots Alliance, Live Nation Entertainment, Denali Therapeutics, Haynes International, NV5 Global, and Johnson Outdoors Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Feb-15-19 09:00AM  Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimers Disease GlobeNewswire
Jan-30-19 09:49AM  Genentech kills big drug study in early Alzheimer's patients American City Business Journals
Jan-08-19 09:00AM  Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for ALS GlobeNewswire
Dec-10-18 09:00AM  Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL201 for Parkinsons Disease GlobeNewswire
Dec-08-18 10:02AM  The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings Benzinga
Nov-26-18 10:04AM  Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics American City Business Journals
Nov-20-18 08:29AM  The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings Benzinga
Nov-19-18 04:30PM  Denali Therapeutics Announces Positive Clinical Results With Its Lead RIPK1 Inhibitor Molecule and Intention to Initiate Patient Studies in Multiple Indications in Collaboration With Sanofi GlobeNewswire -5.36%
Nov-08-18 05:34PM  Eyeing faster path for sickle cell drug, Peninsula biotech plots expansion for a higher price American City Business Journals
04:30PM  Denali Therapeutics Reports Third Quarter 2018 Financial Results and Business Highlights and Announces the Appointment of Jennifer Cook to Board of Directors GlobeNewswire
Nov-01-18 07:30AM  The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal Benzinga +12.85%
02:34AM  [$$] Sanofi, Denali Tie Up $1B Deal The Wall Street Journal
02:00AM  Denali Therapeutics Announces Broad Collaboration with Sanofi to Develop RIPK1 Inhibitors for the Treatment of Neurological and Inflammatory Diseases GlobeNewswire
Oct-23-18 08:40AM  Report: Exploring Fundamental Drivers Behind Q2, Badger Meter, Tiffany, Walgreens Boots Alliance, Intrexon, and Denali Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-19-18 08:03AM  Where Dallas largest hedge funds are placing their long bets American City Business Journals
Oct-03-18 09:00AM  CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials GlobeNewswire
09:00AM  CENTOGENE and Denali Therapeutics Announce Strategic Collaboration to Recruit LRRK2 Patients for Clinical Trials Business Wire
Sep-24-18 03:34PM  Could Denali Therapeutics Incs (NASDAQ:DNLI) Investor Composition Impacts Your Returns? Simply Wall St.
Aug-09-18 04:30PM  Denali Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-01-18 04:30PM  Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program for Parkinsons Disease GlobeNewswire
Jul-23-18 03:05PM  With new attack on Alzheimer's, this young biotech is hiring, grabbing more space American City Business Journals
May-30-18 04:05PM  Denali Therapeutics Announces Early Exercise of Its Option to Acquire F-star Gamma GlobeNewswire
May-21-18 08:52AM  'Bursting at the seams,' this high-profile Peninsula biotech company is moving to a bigger home American City Business Journals
May-18-18 07:07PM  [$$] Life Sciences Investor Biomatics Capital Seeks $300 Million Second Fund The Wall Street Journal
May-11-18 08:00AM  Denali Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire -5.17%
Apr-05-18 08:53AM  Why Denali Therapeutics (DNLI) Could Shock the Market Soon Zacks
Mar-20-18 11:12AM  Here's When You Can Buy Twitter's Stock TheStreet.com
10:48AM  Overall Market Action Is Preventing Aggressive Buying TheStreet.com
Mar-19-18 08:00AM  Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights GlobeNewswire
Feb-08-18 09:00AM  Denali Therapeutics and Lonza Pharma & Biotech Announce Exclusive Partnership to Develop and Produce Biologic Medicines GlobeNewswire
Jan-05-18 07:00AM  Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases Business Wire
Jan-04-18 01:42PM  Snow, Skiing, And A Biotech VC's Outlook For 2018 Forbes
Jan-03-18 11:01AM  Analyst: Denali Therapeutics' Neuroscience Work Could Lead To Near-Term Upside Benzinga
Jan-02-18 12:03PM  3 Key Questions For Denali Therapeutics Investors Benzinga
Dec-28-17 05:14PM  Redwood City biopharma startup hopes to raise up to $98M in what could be Bay Area's first IPO of 2018 American City Business Journals -5.11%
Dec-20-17 05:50PM  Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinsons Disease GlobeNewswire
Dec-12-17 04:10PM  Denali Therapeutics Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Dec-11-17 08:57AM  Bitcoin shorts face massive losses if Winklevosss call hits the mark MarketWatch
Dec-08-17 02:21PM  Nasdaq Welcomes Denali Therapeutics, Inc. (NASDAQ: DNLI) to The Nasdaq Stock Market GlobeNewswire
12:00PM  Denali Therapeutics Enters the Market With a Bang 24/7 Wall St.
11:21AM  Biotech Denali Therapeutics shares surge more than 20% in trading debut MarketWatch
08:37AM  Denali Therapeutics prices IPO at $18 a share, midpoint of price range MarketWatch
06:00AM  Denali Therapeutics Inc. (Nasdaq: DNLI) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its IPO GlobeNewswire
Dec-07-17 07:08PM  Denali Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
05:54PM  [$$] Quanterix Continues String of Life Sciences IPOs The Wall Street Journal
11:25AM  Denali Therapeutics upsizes IPO, to raise $250 million at midpoint of price range MarketWatch
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it is developing LF1, an undisclosed large molecule program to treat neurodegenerative diseases. Additionally, the company has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is based in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schuth Alexander O.COO and SecretaryDec 04Option Exercise5.283,12116,47928,960Dec 05 05:16 PM
Watts Ryan J.President and CEODec 04Sale18.0018,755337,5902,429,304Dec 05 04:29 PM
Schuth Alexander O.COO and SecretaryDec 04Sale18.002,65647,808580,710Dec 05 05:16 PM
Schuth Alexander O.COO and SecretaryDec 04Sale18.003,12156,17825,839Dec 05 05:16 PM
Schuth Alexander O.COO and SecretaryDec 03Option Exercise5.287113,75426,550Dec 05 05:16 PM
Watts Ryan J.President and CEODec 03Sale18.022,51345,2842,448,059Dec 05 04:29 PM
Schuth Alexander O.COO and SecretaryDec 03Sale18.011,01218,226583,366Dec 05 05:16 PM
Schuth Alexander O.COO and SecretaryDec 03Sale18.0171112,80525,839Dec 05 05:16 PM
Schuth Alexander O.COO and SecretaryNov 26Sale18.022294,127584,378Nov 26 05:08 PM
Schuth Alexander O.COO and SecretaryNov 25Sale18.0214,125254,533584,607Nov 26 05:08 PM
Watts Ryan J.President and CEONov 25Sale18.0242,185760,1742,450,572Nov 26 06:17 PM
Schuth Alexander O.COO and SecretaryNov 22Sale18.0064611,628598,732Nov 26 05:08 PM
Watts Ryan J.President and CEONov 22Sale18.001,30023,4002,492,757Nov 26 06:17 PM